Zim Laboratories Limited.

BSE: 541400 NSE: ZIMLAB
Zim Laboratories Limited. - pharma in Nagpur, Maharashtra, India. FY 2026 financials & compliance.
CIN L99999MH1984PLC032172 Incorporated 14 February 1984 ROC Nagpur HQ Nagpur, Maharashtra, India
Active Listed - NSE: ZIMLAB · BSE: 541400 Public Limited Company pharma MSME · Medium
Data last updated
Market Cap
₹710 Cr
ZIMLAB · NSE
Share Price
₹132.12
-0.13% today
Revenue
₹374 Cr
FY 2025-26 · -1.2% YoY
EBITDA
₹30.01 Cr
Margin 8.0%
Net Profit
₹4.35 Cr
FY 2025-26 · -63.5% YoY
P/E (TTM)
200.6x
P/B 2.5x
ROE
1.6%
ROCE 4.8%
Debt / Equity
0.45
Interest cover 131.6x

About Zim Laboratories Limited.

Data last updated:

Zim Laboratories Limited. is a public limited company based in Nagpur, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 14 February 1984 and has been in existence for over 42 years.

The company is registered with the Registrar of Companies (ROC), Nagpur, under CIN L99999MH1984PLC032172. Its GSTIN is 27AAACZ0200E1ZZ (Maharashtra). The company holds 6 GST registrations, of which 5 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 541400 and NSE: ZIMLAB.

The company has an authorised share capital of ₹75 Cr and a paid-up capital of ₹53.55 Cr. It is led by directors including Anwar Siraj Daud (Managing Director) and Zulfiquar Murtaza Kamal (Whole-Time Director).

Its last annual general meeting (AGM) was held on 27 June 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Sadoday Gyan(Ground Floor) Opp.Nadt Nelson Square, Nagpur, Maharashtra, India – 440013.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹374.4 Cr, a decline of 1.2% compared to the previous year. For the same year it recorded a net profit of ₹4.35 Cr (net margin 1.2%) and EBITDA of ₹30.01 Cr (EBITDA margin 8%). The net worth stands at ₹296.15 Cr (up 17.4% YoY). Total assets are valued at ₹422.71 Cr (up 14.2% YoY).

The company has about 586 employees on its provident fund (EPFO) records. Its group structure includes 2 subsidiaries.

The company is associated with 1 brand: Zim Labs. As per MCA filings, the company has open charges of ₹206.19 Cr and satisfied charges of ₹537.82 Cr on record. Court records list 121 cases involving the company, including 64 filed by the company and 57 filed against it; 16 cases are pending. The company has 21 deals on record (20 market trades, 1 funding round), with disclosed funding of ₹50.45 Cr; the latest was in November 2025. Its 7 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 3 larger and 4 smaller; the largest is Maiva Pharma Private Limited with revenue of ₹399.05 Cr. The company has 7 MSME Form 1 returns on record between 2022 and 2024, listing 785 overdue payments to 76 micro and small suppliers.

Zim Laboratories Limited. is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-20-0010559). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website zimlab.in.

Company details

CIN L99999MH1984PLC032172
Registration Number 032172
Incorporation Date 14 February 1984
ROC Nagpur
Listing Status Listed - Listed on NSE (ZIMLAB); Listed on BSE (541400)
Company Status Active
Date of Last AGM 27 June 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-MH-20-0010559

CIN history

Zim Laboratories Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L99999MH1984PLC032172, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L99999MH1984PLC032172Current
U99999MH1984PLC032172Previous
L99999MH1984PTC032172Previous
Key People
Anwar Siraj Daud Managing Director Zulfiquar Murtaza Kamal Whole-Time Director Prakash Pralahadrao Sapkal Whole-Time Director

Recognitions & Rankings of Zim Laboratories Limited

MSME (Udyam registered) Ministry of MSME
Category
Medium (2024-25)
Udyam number
UDYAM-MH-20-0010559

Contact details

Zim Laboratories Limited.'s registered office is in Nagpur, Maharashtra. Its website is zimlab.in. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    zimlab.in
  • Social Media
  • Registered Address
    Sadoday Gyan(Ground Floor) Opp.Nadt Nelson Square, Nagpur, Maharashtra, India – 440013
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Zim Laboratories Limited., buy the company report.

Comprehensive company report
Zim Laboratories Limited. - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Zim Laboratories Limited operates one associated brand: Zim Labs. Each brand links to its own profile.

BrandDescriptionWebsite
Zim Labs
Solid and semisolid dosage forms are developed and manufactured.zimlab.in

Business activity

The main business activity of Zim Laboratories Limited is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Zim Laboratories Limited., buy the company report.

Financials of Zim Laboratories Limited.

FY 2025-26 filings available

Zim Laboratories Limited. reported revenue of ₹374.4 Cr (down 1.2% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹374 Cr
-1.2% YoY
EBITDA
₹30.01 Cr
-31.4% YoY
Profit After Tax
₹4.35 Cr
-63.5% YoY
Net Worth
₹296 Cr
+17.4% YoY
Total Assets
₹423 Cr
+14.2% YoY
Total Debt
₹127 Cr
+7.4% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue374379367399333307278
Revenue growth-1.2%+3.2%-7.8%+19.5%+8.5%+10.6%-
EBITDA30.0143.7241.3351.9940.9734.5822.62
EBITDA margin+8.0%+11.5%+11.3%+13.1%+12.3%+11.3%+8.1%
Profit before tax8.2118.0023.6435.3521.0310.230.08
Net profit4.3511.9217.2624.4314.5411.033.31
Net profit margin+1.2%+3.1%+4.7%+6.1%+4.4%+3.6%+1.2%
EPS (₹)1.092.503.545.018.964.512.04
Balance sheet
Total assets423370351262229243244
Net worth296252239200176161154
Total debt12711811262.1653.4482.3289.85
Cash & bank43.412.4910.467.524.978.353.95
Net working capital170140141117100110101
Cash flow
Cash from operations49.5341.1516.2837.5249.2131.8521.92
Cash from investing(54.54)(39.70)(72.63)(35.06)(14.21)(5.95)(18.79)
Cash from financing28.19(9.10)59.530.55(32.97)(25.97)(2.16)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue94.1810510988.7171.7610996.3392.14
Revenue growth (YoY)+31.2%-3.2%+12.8%-3.7%-12.3%---
Other income0.996.161.702.041.481.711.751.32
EBITDA2.457.1912.815.754.2614.5911.569.53
EBITDA margin+2.6%+6.8%+11.8%+6.5%+5.9%+13.4%+12.0%+10.3%
Depreciation5.375.105.034.984.865.294.885.00
Interest3.643.313.433.163.302.912.732.89
Profit before tax(5.57)4.946.05(0.35)(2.42)8.105.702.96
Tax(1.56)1.201.650.08(0.55)3.221.710.58
Net profit(4.01)3.744.40(0.43)(1.87)4.883.992.38
EPS (₹)(0.75)0.760.90(0.09)(0.38)1.010.820.49
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue370376365397329304274
Revenue growth-1.4%+2.8%-7.8%+20.4%+8.5%+10.7%-
EBITDA29.5743.2740.0951.2037.9331.6419.79
EBITDA margin+8.0%+11.5%+11.0%+12.9%+11.5%+10.4%+7.2%
Profit before tax8.3917.6123.0335.9219.298.59(1.47)
Net profit4.3911.6616.7625.0113.019.011.76
Net profit margin+1.2%+3.1%+4.6%+6.3%+4.0%+3.0%+0.6%
EPS (₹)1.112.413.445.138.013.461.08
Balance sheet
Total assets413362344256224239242
Net worth286245232194170157152
Total debt12711811262.1653.4482.3289.85
Cash & bank37.000.820.752.212.097.862.83
Net working capital15112612910589.0710295.65
Cash flow
Cash from operations47.6650.6011.4735.2347.0331.9021.29
Cash from investing(57.41)(41.31)(71.94)(35.21)(14.42)(5.70)(18.82)
Cash from financing28.19(9.10)59.530.55(32.97)(25.96)(2.16)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue93.0510310888.3971.4310995.4089.72
Revenue growth (YoY)+30.3%-5.2%+13.0%-1.5%-12.9%---
Other income0.996.161.712.041.481.551.761.32
Total expenses90.6496.2895.3182.2267.0993.2883.6381.33
EBITDA2.416.5712.506.174.3415.2411.778.39
EBITDA margin+2.6%+6.4%+11.6%+7.0%+6.1%+14.0%+12.3%+9.4%
Depreciation5.174.904.854.834.795.234.774.97
Interest3.643.313.433.163.302.912.732.89
Profit before tax(5.41)4.525.930.22(2.27)8.656.031.85
Tax(1.55)1.241.670.11(0.59)3.231.680.64

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 22 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue94.1810510988.7171.7610996.3392.14
Revenue growth (YoY)+31.2%-3.2%+12.8%-3.7%-12.3%---
Other income0.996.161.702.041.481.711.751.32
EBITDA2.457.1912.815.754.2614.5911.569.53
EBITDA margin+2.6%+6.8%+11.8%+6.5%+5.9%+13.4%+12.0%+10.3%
Depreciation5.375.105.034.984.865.294.885.00
Interest3.643.313.433.163.302.912.732.89
Profit before tax(5.57)4.946.05(0.35)(2.42)8.105.702.96
Tax(1.56)1.201.650.08(0.55)3.221.710.58
Net profit(4.01)3.744.40(0.43)(1.87)4.883.992.38
EPS (₹)(0.75)0.760.90(0.09)(0.38)1.010.820.49
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue374379367399333307278
Revenue growth-1.2%+3.2%-7.8%+19.5%+8.5%+10.6%-
Other income11.385.785.186.414.402.344.52
Total expenses344335326347292273255
Employee cost63.9060.7653.3449.3240.0735.7635.35
EBITDA30.0143.7241.3351.9940.9734.5822.62
EBITDA margin+8.0%+11.5%+11.3%+13.1%+12.3%+11.3%+8.1%
Depreciation19.9820.1115.9517.4716.0315.7914.41
Interest13.2011.396.925.588.3110.9012.65
Profit before tax8.2118.0023.6435.3521.0310.230.08
Tax2.375.846.3910.926.492.91(3.22)
Net profit4.3511.9217.2624.4314.5411.033.31
Net profit margin+1.2%+3.1%+4.7%+6.1%+4.4%+3.6%+1.2%
EPS (₹)1.092.503.545.018.964.512.04
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital53.5048.7348.7348.7316.2416.2416.18
Reserves & surplus240202190152159145138
Shareholders' funds (net worth)296252239200176161154
Minority interest0.000.000.000.000.000.000.00
Secured loans12011210659.5751.3181.0789.44
Unsecured loans6.085.635.422.592.131.250.41
Total debt12711811262.1653.4482.3289.85
Total liabilities423370351262229243244
Assets
Gross block290275267199180165159
Net block162164161109106107116
Capital work in progress95.5370.4642.2826.9911.7510.689.62
Investments0.050.050.050.050.050.050.05
Inventories93.7786.4781.2653.7175.2854.3556.39
Sundry debtors10910710095.2589.5272.2567.93
Cash & bank balances43.412.4910.467.524.978.353.95
Loans & advances29.5835.4235.7634.4842.3656.8153.76
Total current assets276231228191212192182
Total current liabilities10690.9386.2174.2611281.7181.01
Net working capital170140141117100110101
Total assets423370351262229243244
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash1.959.606.423.421.391.460.50
Net cash from operating activities49.5341.1516.2837.5249.2131.8521.92
Net cash from investing activities(54.54)(39.70)(72.63)(35.06)(14.21)(5.95)(18.79)
Net cash from financing activities28.19(9.10)59.530.55(32.97)(25.97)(2.16)
Net change in cash23.18(7.65)3.183.002.03(0.07)0.96
Closing cash43.412.4910.467.524.978.353.95
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-1.2%+3.2%-7.8%+19.5%+8.5%+10.6%-
EBITDA growth-31.4%+5.8%-20.5%+26.9%+18.5%+52.9%-
PBT growth-54.4%-23.9%-33.1%+68.1%+105.6%--99.6%
Net income growth-63.5%-30.9%-29.4%+68.0%+31.8%+233.2%-
Revenue CAGR (3Y)-2.1%+4.4%+6.1%+12.8%-0.2%+4.0%+5.7%
EBITDA CAGR (3Y)-16.7%+2.2%+6.1%+32.0%-0.9%-0.2%-10.4%
Profitability & leverage
Net income margin+1.6%+3.2%+4.7%+6.1%+4.4%+2.4%+1.2%
Return on capital employed+4.8%+8.2%+10.0%+16.7%+12.4%+10.8%+5.4%
Return on net worth+1.6%+5.0%+7.9%+13.0%+8.7%+7.0%+2.2%
Debt / equity0.450.470.400.310.400.550.55
Long-term debt / equity0.220.230.200.190.210.240.25
Interest cover131.6148.2427.2716.1633.3258.01154.08
Efficiency & per share
Fixed asset turnover1.331.401.582.101.931.891.88
Inventory turnover4.154.525.446.185.145.554.98
Debtors turnover3.473.663.764.314.124.383.45
EPS (₹)1.092.503.545.018.964.512.04
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)54.9051.4949.0041.12108.1898.9795.06
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue93.0510310888.3971.4310995.4089.72
Revenue growth (YoY)+30.3%-5.2%+13.0%-1.5%-12.9%---
Other income0.996.161.712.041.481.551.761.32
Total expenses90.6496.2895.3182.2267.0993.2883.6381.33
EBITDA2.416.5712.506.174.3415.2411.778.39
EBITDA margin+2.6%+6.4%+11.6%+7.0%+6.1%+14.0%+12.3%+9.4%
Depreciation5.174.904.854.834.795.234.774.97
Interest3.643.313.433.163.302.912.732.89
Profit before tax(5.41)4.525.930.22(2.27)8.656.031.85
Tax(1.55)1.241.670.11(0.59)3.231.680.64
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue370376365397329304274
Revenue growth-1.4%+2.8%-7.8%+20.4%+8.5%+10.7%-
Other income11.395.624.696.434.512.454.66
Total expenses341332325345292272255
Employee cost60.1056.4150.8146.4738.6334.4834.58
EBITDA29.5743.2740.0951.2037.9331.6419.79
EBITDA margin+8.0%+11.5%+11.0%+12.9%+11.5%+10.4%+7.2%
Depreciation19.3719.8914.8316.1314.8414.6113.27
Interest13.2011.396.925.588.3110.8912.65
Profit before tax8.3917.6123.0335.9219.298.59(1.47)
Tax2.445.876.2810.916.282.97(3.22)
Net profit4.3911.6616.7625.0113.019.011.76
Net profit margin+1.2%+3.1%+4.6%+6.3%+4.0%+3.0%+0.6%
EPS (₹)1.112.413.445.138.013.461.08
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital53.5048.7348.7348.7316.2416.2416.18
Reserves & surplus230194183145154141136
Shareholders' funds (net worth)286245232194170157152
Secured loans12011210659.5751.3181.0789.44
Unsecured loans6.085.635.422.592.131.250.41
Total debt12711811262.1653.4482.3289.85
Total liabilities413362344256224239242
Assets
Gross block281268260192174160153
Net block160164160107103103111
Capital work in progress89.4065.6740.2526.2611.4210.469.62
Investments17.6613.048.238.188.188.088.08
Inventories93.7786.4781.2653.7175.2854.3556.39
Sundry debtors92.2893.6810088.3680.8963.9563.34
Cash & bank balances37.000.820.752.212.097.862.83
Loans & advances29.3835.3835.6134.3742.3356.8153.73
Total current assets252216218179201183176
Total current liabilities10290.7788.6873.7211280.9180.64
Net working capital15112612910589.0710295.65
Total assets413362344256224239242
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.360.171.110.540.900.670.36
Net cash from operating activities47.6650.6011.4735.2347.0331.9021.29
Net cash from investing activities(57.41)(41.31)(71.94)(35.21)(14.42)(5.70)(18.82)
Net cash from financing activities28.19(9.10)59.530.55(32.97)(25.96)(2.16)
Net change in cash18.430.19(0.94)0.57(0.36)0.230.31
Closing cash37.000.820.752.212.097.862.83
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-1.4%+2.8%-7.8%+20.4%+8.5%+10.7%-
EBITDA growth-31.7%+7.9%-21.7%+35.0%+19.9%+59.9%-
PBT growth-52.4%-23.5%-35.9%+86.2%+124.6%+9998.0%-
Net income growth-62.4%-30.4%-33.0%+92.2%+44.4%+411.9%-
Revenue CAGR (3Y)-2.2%+4.5%+6.4%+13.1%-0.2%+3.8%+5.3%
EBITDA CAGR (3Y)-16.7%+4.5%+8.2%+37.3%-3.7%-2.3%-14.4%
Profitability & leverage
Net income margin+1.6%+3.1%+4.6%+6.3%+4.0%+1.9%+0.6%
Return on capital employed+4.9%+8.2%+10.0%+17.3%+11.9%+10.2%+4.7%
Return on net worth+1.7%+4.9%+7.9%+13.7%+8.0%+5.8%+1.2%
Debt / equity0.460.480.410.320.410.560.55
Long-term debt / equity0.160.170.150.160.210.160.20
Interest cover129.4148.7227.4015.9135.9963.95194.02
Efficiency & per share
Fixed asset turnover1.351.421.622.171.981.941.94
Inventory turnover4.114.485.426.155.085.484.92
Debtors turnover3.983.883.884.694.554.773.57
EPS (₹)1.112.413.445.138.013.461.08
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)53.0749.9047.6039.85104.7396.6993.79

To see the full year-wise statements and ratios of Zim Laboratories Limited., buy the company report.

Board of directors of Zim Laboratories Limited.

Zim Laboratories Limited has 8 current directors and 14 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Zulfiquar Murtaza Kamal
Also directs: Zim Health Technologies Limited, Zim Thinorals Private Limited, Falcon Knowledge Services Private Limited and 1 more
Whole-Time Director19 Oct 201214 Years 0 MonthsCurrent
Prakash Pralahadrao Sapkal
Also directs: Zim Thinorals Private Limited
Whole-Time Director22 Nov 201312 Years 11 MonthsCurrent
Niraj Pukhraj DhadiwalWhole-Time Director22 Nov 201312 Years 11 MonthsCurrent
Kavita LoyaDirector21 Sep 20179 Years 1 MonthsCurrent
Padmakar Shrinivas JoshiDirector21 Sep 20179 Years 1 MonthsCurrent
Anwar Siraj Daud
Also directs: Zim Health Technologies Limited, Zim Thinorals Private Limited
Managing Director01 Apr 200917 Years 6 MonthsCurrent
Showing 6 of 8 current directors. View all directors

Peer comparison

Zim Laboratories Limited. is compared with the 7 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Maiva Pharma Private Limited₹399.05 Cr (FY 2025)38.0%Bangalore, Karnataka, India
Rusan Pharma Limited₹392.15 Cr (FY 2025)9.0%Mumbai, Maharashtra, India
Hetero Biopharma Limited₹387.48 Cr (FY 2024)13.0%Hyderabad, Telangana, India
Rajasthan Antibiotics Ltd₹383.3 Cr (FY 2025)1.0%New Delhi, Delhi, India
Marc Laboratories Limited₹383.21 Cr (FY 2025)3.0%New Delhi, Delhi, India
Caplin Steriles Limited₹377.24 Cr (FY 2025)18.0%Chennai, Tamil Nadu, India
NGL Fine-Chem Limited₹376.89 Cr (FY 2025)7.0%Mumbai, Maharashtra, India
Zim Laboratories Limited.this company₹374.4 Cr (FY 2026)₹4.35 Cr1.2%-1.2%586Nagpur, Maharashtra, India

To see the full peer comparison of Zim Laboratories Limited., buy the company report.

Auditor

Zim Laboratories Limited. is audited by Walker Chandiok & Co LLP for the financial year 2025.

Auditor firmFinancial yearFirm registration number
Walker Chandiok & Co LLPFY 2025001076N/N500013

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 30.40%, foreign institutional investors hold 0.00%, domestic institutional investors hold 1.40% and retail and other public shareholders hold 68.30%.

Promoters: 30.40%DII (Domestic Institutional): 1.40%Retail & Others: 68.30%
Sep 2026
QUARTER
30.40% Promoters
1.40% DII (Domestic Institutional)
68.30% Retail & Others
Promoter holding - history
Now 30.40% · Sep 2026High 33.30% · Dec 2025Low 30.40% · Jun 2026
29%30.5%32%33.5%35%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 33.30%Mar 2026: 33.30%Jun 2026: 30.40%Sep 2026: 30.40%33.30%30.40%30.40%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters30.40%30.40%33.30%33.30%
Public69.60%69.60%66.70%66.70%

Charges & borrowings

Open charges
₹206.19 Cr
Satisfied charges
₹537.82 Cr
Breakdown by lending institutions
Bank of India₹181.19 Cr
Others₹25.00 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
31 Oct 2023100818093Others₹25 CrOpen
01 Feb 201310412179Bank of India₹181.19 CrOpen
31 Jan 2026101237086Others₹7 CrSatisfied
28 Apr 2025101086825Bank of India₹6.5 CrSatisfied
29 May 2024100934913Others₹16 CrSatisfied

To see the full charge records of Zim Laboratories Limited., buy the company report.

Total charge records: 52 View all charges

Deals & funding

Zim Laboratories Limited. has 21 deals on record (20 market trades, 1 funding round), with disclosed funding of ₹50.45 Cr; the latest was in November 2025.

Total deals
21
Market trades
20
Funding round
1
Disclosed funding
₹50.45 Cr

Deals on record (5 of 21)

WhenDealAmountParties
Nov 2025Market trade₹28.21 CrBuyer: Elimath Advisors Private Limited
Seller: an individual
Oct 2025Market trade₹10.8 CrBuyer: Elimath Advisors Private Limited
Seller: an individual
Mar 2025Market trade₹4.46 CrBuyer: Yuga Stocks & Commodities Private Limited
Seller: Yuga Stocks & Commodities Private Limited
Mar 2025Market trade₹5.43 CrBuyer: an individual
Seller: Elimath Advisors Private Limited
Feb 2025Market trade₹8.99 CrBuyer: an individual
Seller: Elimath Advisors Private Limited

To see the full deal history of Zim Laboratories Limited., buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

Zim Laboratories Limited. has 7 MSME Form 1 returns on record between 2022 and 2024, listing 785 overdue payments to 76 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 76)

SupplierAmount dueDue sinceReported on
Anil Hardware
an individual supplier
Singh Commando Security Force Private Limited
Adriean Remedies Private Limited
Umang Pharmatech Pvt Ltd

To see the full MSME payment records of Zim Laboratories Limited., buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Zim Laboratories Limited has 2 subsidiary companies. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.

2
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Zim Health Technologies LimitedU24100MH2009PLC193240
Zim Thinorals Private LimitedU24297MH2021PTC360634

To see the full group structure of Zim Laboratories Limited., buy the company report.

Employees & EPFO

Zim Laboratories Limited. has a workforce of 586 employees on its EPFO records as of Jan 19, 2026, across 1 active EPFO establishment.

Employee count
586
Active EPFO establishments
1
Employee growth
-6.39%

GST

Zim Laboratories Limited has 6 GST registrations: 5 active and 1 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
6
Active
5
Cancelled / inactive
1
GSTINStateStatusRegistered on
27AAACZ0200E1ZZMaharashtraActive01 Jul 2017
27AAACZ0200E2ZYMaharashtraActive19 Sep 2024
07AAACZ0200E1Z1DelhiActive08 May 2018
33AAACZ0200E1Z6Tamil NaduActive18 May 2018

To see the full GST registrations and return filing status of Zim Laboratories Limited., buy the company report.

Recent activity

Zim Laboratories Limited. has 34 board changes on record since 1998: 21 appointments and 13 cessations. The latest: Ashok Bhatia was appointed as Director on 01 Apr 2025.

Charges
A charge registered on 31 Jan 2026 via Charge ID 101237086 with Others was fully satisfied on 24 Jun 2026.
Charges
A charge with Bank Of India of Rs. 181.19 Cr registered on 01 Feb 2013 with Charge ID 10412179 was modified on 20 May 2026.
Filing
Zim Laboratories Limited. has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Nagpur.
Charges
A charge with Others of Rs. 25.00 Cr registered on 31 Oct 2023 with Charge ID 100818093 was modified on 24 Mar 2026.
Charges
A charge with Others amounted to Rs. 7.00 Cr with Charge ID 101237086 was registered on 31 Jan 2026.
Charges
A charge registered on 28 Apr 2025 via Charge ID 101086825 with Bank Of India was fully satisfied on 27 Oct 2025.
AGM
Zim Laboratories Limited. last Annual general meeting of members was held on 27 Jun 2025 as per latest MCA records.
Charges
A charge with Bank Of India amounted to Rs. 6.50 Cr with Charge ID 101086825 was registered on 28 Apr 2025.
Appointed
Ashok Bhatia was appointed as Director.
Ceased
Kakasaheb Ramoo Mahadik ceased to be Director.
Charges
A charge registered on 29 May 2024 via Charge ID 100934913 with Others was fully satisfied on 09 Dec 2024.
Charges
A charge registered on 05 Apr 2024 via Charge ID 100902153 with Bank Of India was fully satisfied on 07 Aug 2024.

135 earlier events are in the company report.

News

Frequently asked questions

Zim Laboratories Limited is an active public limited company based in Nagpur, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 14 February 1984 (42+ years old) and is registered under CIN L99999MH1984PLC032172. Listed on BSE: 541400 and NSE: ZIMLAB.

Zim Laboratories Limited reported revenue of ₹374.4 Cr for FY 2025-26 (down 1.2% YoY) based on consolidated financials.

Zim Laboratories Limited has 8 current directors:

The latest financial statements of Zim Laboratories Limited on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 27 June 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Zim Laboratories Limited is 27AAACZ0200E1ZZ, registered in Maharashtra. The company has 6 GST registrations in all, of which 5 are active and 1 is cancelled or inactive. Other active GSTINs include 27AAACZ0200E2ZY (Maharashtra), 07AAACZ0200E1Z1 (Delhi), 33AAACZ0200E1Z6 (Tamil Nadu).

The CIN (Corporate Identification Number) of Zim Laboratories Limited is L99999MH1984PLC032172. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Zim Laboratories Limited is a listed company as per MCA records. Its shares are listed on both BSE (code: 541400) and NSE (symbol: ZIMLAB).

Zim Laboratories Limited has 121 court cases on record: 64 filed by the company and 57 filed against it. 16 are pending. Most are in the district courts.

Zim Laboratories Limited was incorporated on 14 February 1984, making it 42+ years old. It is registered with the Registrar of Companies, Nagpur.

Zim Laboratories Limited has 21 deals on record (20 market trades, 1 funding round), with disclosed funding of ₹50.45 Cr; the latest was in November 2025.

The peers of Zim Laboratories Limited by revenue are Maiva Pharma Private Limited, Rusan Pharma Limited, Hetero Biopharma Limited, Rajasthan Antibiotics Ltd, Marc Laboratories Limited and 2 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Ashok Bhatia was appointed as Director on 01 Apr 2025. Kakasaheb Ramoo Mahadik ceased to be Director on 01 Apr 2025. Kakasaheb Ramoo Mahadik was appointed as Director on 01 Apr 2022. Zim Laboratories Limited has 34 board changes on record in total.